The KRAS G12C inhibition group (30 mg kg‐1 AMG510) showed persistent tumor growth in these experiments, highlighting the impact of the drug resistance to AMG510 of the CO‐04‐0070 model. This evidence concerns the gene KRAS and neoplasm.